- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01703624
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease
An Investigation of the Efficacy, Tolerability and Safety of a Range of Doses of Orally Inhaled Glycopyrronium Bromide (PSX1002-GB pMDI) in Male and Female Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease
This is an investigation of the beneficial effects, tolerability and safety of a range of single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female patients with moderate or severe chronic obstructive pulmonary disease (COPD). COPD is a long term and progressive disease of the lungs, generally caused by cigarette smoking, but other factors may be involved. Glycopyrronium bromide (GB) appears to be particularly useful in dilating the constricted airways of such patients, with a duration of action variously described as being between 12 and 24 hours.
This study will investigate how well tolerated and safe this medication is at a range of doses. It will also help in the selection of a suitable dose for larger and repeat dose studies, based on measures of lung response. It will also help to determine how often the medication should be given; twice daily, or once daily.
Up to 40 patients will be enrolled into the study, ranging in age from 40 to 75 years of age. Patients will be medically assessed before participation to ensure their suitability. The study will take place in one centre in the UK over five sessions; at each session one dose (2 puffs) of GB or one dose (2 puffs) of placebo will be administered from a simple inhaler device. Neither staff nor patients will know which dose, or if placebo, is being taken. Lung function will be measured for up to 26 hours after the administration of each dose using standard spirometry equipment. Blood samples will be taken over a 24-hour period to check the blood levels of GB. There will be a period of about a week between each dosing session. Patients will be medically reviewed after the study to confirm that no untoward effects are present.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom, M23 9QZ
- Medicines Evaluation Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age 40-75 years, inclusive
- A clinical diagnosis of moderate to severe COPD (GOLD guidelines)
- Current smokers or ex-smokers with at least 10-pack year smoking history
- Post-bronchodilator FEV1/FVC ratio < 70 % at Screen
- Post-bronchodilator FEV1 ≥ 40 % to < 80 % of predicted at Screen
- Demonstrated to be responsive to ipratropium (defined as at least an 100ml increase in FEV1 following ipratropium 80 µg)
- Ability to perform acceptable spirometry (ATS/ERS guidelines)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Females who are pregnant or lactating at the Screening Visit, or if of childbearing potential not using an acceptable means of birth control throughout the study (defined in protocol)
- Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data (defined in protocol)
- Recent history of hospitalisation due to an exacerbation of airway disease within three months prior to the Screening Visit or randomisation
- Need for increased treatments of COPD within six weeks prior to the Screening Visit or randomisation
- Primary diagnosis of asthma
- Prior lung volume reductions surgery or history of chest/lung irradiation
- Regular use of daily oxygen therapy
- Use of systemic steroids within three months prior to the Screening Visit or during the run-in period
- Respiratory tract infection within six weeks prior to the Screening Visit.
- History of tuberculosis, bronchiectasis or other non-specific pulmonary disease
- History of urinary retention or bladder neck obstructive type symptoms
- History of narrow-angle glaucoma
- Clinically significant abnormal ECG
- Positive Hepatitis B antigen or positive Hepatitis C antibody
- Positive screening test for HIV antibodies
- Current evidence or history of excessive use or abuse of alcohol in the opinion of the Investigator
- Current evidence or history of abusing legal drugs or use of illegal drugs or substances in the opinion of the Investigator
- Donation of 450 ml or more of blood within eight weeks of the Screening Visit
- History of hypersensitivity or intolerance to aerosol medications
- Participation in another investigational drug study where drug was received within 30 days prior to the Screening Visit.
- Inability to comply with study procedures or with study treatment intake, including inability to be trained and/or inability to demonstrate good inhaler technique with Vitalograph AIM
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: glycopyrronium bromide 12.5mcg
glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
|
glycopyrronium bromide suspension in HFA
Other Names:
|
Experimental: glycopyrronium bromide 25mcg
glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
|
glycopyrronium bromide suspension in HFA
Other Names:
|
Experimental: glycopyrronium bromide 50mcg
glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
|
glycopyrronium bromide suspension in HFA
Other Names:
|
Experimental: glycopyrronium bromide 100mcg
glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
|
glycopyrronium bromide suspension in HFA
Other Names:
|
Placebo Comparator: placebo
placebo single dose via pressurised metered dose inhaler (pMDI)
|
glycopyrronium bromide suspension in HFA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)
Time Frame: From time zero to 24-hours
|
FEV1 time-adjusted AUC(0-24 hours)
|
From time zero to 24-hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)
Time Frame: From time zero to 12-hours
|
FEV1 time-adjusted AUC(0-12 hours)
|
From time zero to 12-hours
|
Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC)
Time Frame: From 12 to 24-hours
|
FEV1 time-adjusted AUC(12-24 hours)
|
From 12 to 24-hours
|
Forced Expiratory Volume in one second (FEV1)
Time Frame: From time zero to 24-hours
|
Serial FEV1 time-point assessments
|
From time zero to 24-hours
|
Forced Vital Capacity (FVC) Area Under the Curve (AUC)
Time Frame: From time zero to 24-hours
|
FVC time-adjusted AUC(0-24 hours), AUC(0-12 hours), AUC(12-24 hours), serial time-point assessment
|
From time zero to 24-hours
|
Forced Expiratory Volume in one second (FEV1) / Forced Vital Capacity (FVC) ratio
Time Frame: From time zero to 24-hours
|
Serial FEV1/FVC time-point assessment
|
From time zero to 24-hours
|
Number of subjects reporting adverse events after each treatment as a measure of safety and tolerability
Time Frame: An average of 9 weeks
|
Adverse event monitoring will begin once a subject provides informed consent and will continue until study participation is concluded; incidence rates will be summarised by system organ class, preferred term, severity and by reported relationship to study drug for each treatment
|
An average of 9 weeks
|
Systolic blood pressure
Time Frame: From time zero to 24-hours
|
Descriptive statistics will be presented for the serial measurements by treatment
|
From time zero to 24-hours
|
Diastolic blood pressure
Time Frame: From time zero to 24-hours
|
Descriptive statistics will be presented for the serial measurements by treatment
|
From time zero to 24-hours
|
Peripheral pulse rate
Time Frame: From time zero to 24-hours
|
Descriptive statistics will be presented for the serial measurements by treatment
|
From time zero to 24-hours
|
Electrocardiography (ECG)
Time Frame: From time zero to 24-hours
|
Descriptive statistics will be presented for the serial measurements of each of the standard electrocardiographic (12-lead) parameters by treatment
|
From time zero to 24-hours
|
Clinical hematology
Time Frame: An average of 9 weeks
|
Clinical hematology measures will be taken at the Screening Visit and at the Safety Follow-up Visit and will consist of: red blood cell count, hemoglobin, hematocrit, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, white blood cell count, differential white blood cell count and platelet count.
Data will be summarised using descriptive statistics
|
An average of 9 weeks
|
Clinical chemistry
Time Frame: An average of 9 weeks
|
Clinical chemistry measures will be taken at the Screening Visit and at the Safety Follow-up Visit and will consist of: sodium, potassium, urea, creatinine, uric acid, glucose, calcium, inorganic phosphorus, total bilirubin, alkaline phosphatase, alanine transaminase, aspartate transminase, gamma glutamyl transferase, creatine kinase, total protein, albumin, cholesterol and triglycerides.
Data will be summarised using descriptive statistics
|
An average of 9 weeks
|
Plasma glycopyrronium bromide concentration-time Area Under the Curve (AUC)
Time Frame: From time zero to 24-hours
|
AUC (0-infinity) will be extrapolated from serial measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Plasma glycopyrronium bromide peak concentration (Cmax)
Time Frame: From time zero to 24-hours
|
Cmax will be obtained from serial measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Plasma glycopyrronium bromide time to maximum concentration (tmax)
Time Frame: From time zero to 24-hours
|
tmax will be calculated from serial measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Plasma glycopyrronium bromide concentration elimination half-life (t1/2)
Time Frame: From time zero to 24-hours
|
t1/2 will be calculated from serial measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Glycopyrronium bromide total plasma clearance following extravascular administration (CL/F)
Time Frame: From time zero to 24-hours
|
CL/F will be calculated from serial plasma concentration measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Glycopyrronium bromide apparent volume of distribution following extravascular administration (Vz/F)
Time Frame: From time zero to 24-hours
|
Vz/F will be calculated from serial plasma concentration measures taken over time zero to 24-hours.
The descriptive statistics presented by treatment will be: minimum, median, maximum, geometric mean, arithmetic mean and arithmetic standard deviation
|
From time zero to 24-hours
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Geoff Down, MB BS FFPM, Prosonix Limited, Oxford, UK
- Principal Investigator: Dave Singh, MA MD MRCP, Medicines Evaluation Unit, Manchester, UK
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Anticonvulsants
- Glycopyrrolate
- Bromides
Other Study ID Numbers
- PSX100201
- 2012-003791-40 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on glycopyrronium bromide
-
Novartis PharmaceuticalsCompletedCOPDGermany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
-
Novartis PharmaceuticalsRecruitingAsthmaSpain, Hungary, United Kingdom, South Africa, Colombia, Bulgaria, Poland, Guatemala
-
NovartisCompletedChronic Obstructive Pulmonary DiseaseUnited States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
-
University of SaskatchewanCompleted
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingChronic Obstructive Pulmonary DiseaseChina
-
Novartis PharmaceuticalsCompletedCOPDGermany, Spain, United Kingdom, Italy
-
Pearl Therapeutics, Inc.Completed
-
Dr. August Wolff GmbH & Co. KG ArzneimittelCompletedPrimary Axillary HyperhidrosisGermany
-
University of MilanFondazione Salvatore MaugeriCompletedChronic Obstructive Pulmonary DiseaseItaly
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan